Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems, Eversense, Eversense XL, and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every five minutes to a mobile app on the user's smartphone. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device. Its CGM system continually and accurately measures a person's glucose levels for up to six months.

Employees

117

Sector

Medical Equipment, Supplies & Distribution

Calendar

08-06 - Q2 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
17/07/25	0.5631 $	+4.98%	20,320,139
16/07/25	0.5364 $	+5.07%	8,830,265
15/07/25	0.5105 $	+3.57%	14,945,547
14/07/25	0.4929 $	-0.80%	4,877,401
11/07/25	0.4969 $	-0.62%	4,854,682

Delayed Quote Nyse, July 17, 2025 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.5631USD

Average target price

1.550USD

Spread / Average Target

+175.26%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nyse Other stock markets 21:00:00 17/07/2025 BST			5-day change	1st Jan Change
0.5631 ^USD	+4.98%		+12.62%	+7.59%

07-15	TD Cowen Initiates Senseonics Holdings at Buy With $1.25 Price Target	MT
06-20	Senseonics Holdings, Inc., Q1 2025 Earnings Call, May 08, 2025

Capitalization	455M 393M 367M 340M 626M 39.19B 703M 4.44B 1.67B 18.35B 1.71B 1.67B 67.64B	P/E ratio 2025 *	-7.22x	P/E ratio 2026 *	-9.08x
Enterprise value	455M 393M 367M 340M 626M 39.19B 703M 4.44B 1.67B 18.35B 1.71B 1.67B 67.64B	EV / Sales 2025 *	12.7x	EV / Sales 2026 *	7.74x
Free-Float	93.84%	Yield 2025 *	-	Yield 2026 *	-

TD Cowen Initiates Senseonics Holdings at Buy With $1.25 Price Target	07-15	MT
Senseonics Holdings, Inc., Q1 2025 Earnings Call, May 08, 2025	06-20
Senseonics Raises $77.8 Million from Public Offering, Placement	05-21	MT
Senseonics Prices $50 Million Public Offering	05-16	MT
Senseonics Announces Pricing Of $50 Million Public Offering At $0.50 Per Share	05-16	RE
Senseonics Kicks Off $50 Million Stock Offering; Discloses Private Placement of Up to $25 Million With Abbott Laboratories	05-15	MT
Senseonics Holdings Inc Enters Securities Purchase Agreement With Abbott	05-15	RE
Senseonics Holdings, Inc. announced that it expects to receive $25 million in funding from Abbott Laboratories	05-14	CI
Senseonics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-08	CI
Senseonics Holdings, Inc. Provides Earnings Guidance for the Full-Year 2025	05-08	CI
Sequel Med Tech and Senseonics Holdings, Inc. Integrate Technologies to Create First Automated Insulin Delivery System with One-Year Continuous Glucose Monitor	04-29	CI
Mizuho Initiates Senseonics at Outperform With $2 Price Target	04-10	MT
Senseonics Holdings, Inc.(NYSEAM:SENS) added to S&P Healthcare Equipment Select Industry Index	03-23	CI

TD Cowen Initiates Senseonics Holdings at Buy With $1.25 Price Target	07-15	MT
Mizuho Initiates Senseonics at Outperform With $2 Price Target	04-10	MT
HC Wainwright Adjusts Senseonics Price Target to $2 From $3, Maintains Buy Rating	15/08/23	MT
Jefferies Starts Senseonics Holdings at Underperform With $0.50 Price Target	19/07/23	MT
HC Wainwright Adjusts Senseonics Holdings' Price Target to $3 from $6, Keeps Buy Rating	25/07/22	MT

Senseonics Holdings, Inc. Share Price

Equities

SENS

US81727U1051

Medical Equipment, Supplies & Distribution

Valuation: Senseonics Holdings, Inc.

Chart: Senseonics Holdings, Inc.

Latest news: Senseonics Holdings, Inc.

Last Transcript: Senseonics Holdings, Inc.

Analysts' recommendations: Senseonics Holdings, Inc.

Press Releases: Senseonics Holdings, Inc.

News in other languages: Senseonics Holdings, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Senseonics Holdings, Inc.

ETFs: Senseonics Holdings, Inc.

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Senseonics Holdings, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for August 6, 2025 at 4:30 P.M. Eastern Time	07-16	AQ
Senseonics Holdings, Inc. to Host In-Person and Virtual Analyst Event at ADA 2025: Eversense® 365 Continuous Glucose Monitoring System for People with Diabetes	06-04	AQ
Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters’ Option to Purchase Additional Shares, and Closing of Private Placement	05-21	AQ
Senseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private Placement	05-16	AQ
Senseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private Placement	05-15	AQ

DexCom, Inc. : Una herramienta imprescindible para el cuidado de la diabetes	15/07/24
Senseonics : annonce l'obtention du marquage CE pour le système Eversense XL®	13/09/17
Senseonics : gibt CE-Zulassung für das Eversense® XL CGM-System bekannt	13/09/17
Senseonics : annuncia l’approvazione del marchio CE per il sistema CGM Eversense® XL	13/09/17
Senseonics : en tête de file des efforts de développement d’un « Pancréas artificiel » à long terme à utiliser dans l’essai clinique international en boucle fermée	25/07/17

1 day	+4.98%
1 week	+12.62%
Current month	+18.20%
1 month	+12.71%
3 months	-6.13%
6 months	-33.59%
Current year	+7.59%

1 week	0.49	0.63
1 month	0.45	0.63
Current year	0.43	1.4
1 year	0.25	1.4
3 years	0.25	2.44
5 years	0.25	5.56
10 years	0.25	5.56

Manager	Title	Age	Since
Timothy Goodnow CEO	Chief Executive Officer	63	30/11/2015
Rick Sullivan DFI	Director of Finance/CFO	-	31/08/2022
Francine Kaufman CTO	Chief Tech/Sci/R&D Officer	74	05/03/2019

Director	Title	Age	Since
Stephen DeFalco CHM	Chairman	64	30/11/2015
Edward Fiorentino BRD	Director/Board Member	66	30/11/2015
Douglas Prince BRD	Director/Board Member	71	30/11/2015

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SENSEONICS HOLDINGS, INC.	+4.98%	+12.62%	+19.81%	-51.03%	455M
ABBOTT LABORATORIES	-8.52%	-9.80%	+15.12%	+10.74%	210B
MEDTRONIC PLC	-0.28%	+0.15%	+10.18%	+0.46%	115B
CENCORA, INC.	-1.16%	-0.99%	+30.74%	+106.99%	57.06B
BECTON, DICKINSON AND COMPANY	+1.48%	+1.92%	-22.71%	-24.39%	51.85B
HOYA CORPORATION	+0.41%	+3.22%	-4.41%	+46.73%	42.31B
DEXCOM, INC.	-0.04%	-1.59%	-26.62%	+6.27%	32.98B
TERUMO CORPORATION	-1.27%	-1.81%	-13.09%	+11.85%	24.3B
STERIS PLC	-1.33%	-2.66%	-1.80%	+7.33%	22.09B
SARTORIUS STEDIM BIOTECH	-0.75%	-6.22%	+11.28%	-43.73%	21.75B
Average	+0.29%	-0.33%	+1.85%	+7.12%	57.72B
Weighted average by Cap.	+0.04%	-3.63%	+6.49%	+15.25%

	2025 *	2026 *
Net sales	35.9M 30.98M 28.89M 26.77M 49.36M 3.09B 55.38M 350M 132M 1.45B 135M 132M 5.33B	58.82M 50.76M 47.34M 43.86M 80.87M 5.06B 90.73M 574M 216M 2.37B 221M 216M 8.74B
Net income	-58.08M -50.12M -46.74M -43.31M -79.85M -5B -89.59M -567M -213M -2.34B -218M -213M -8.63B	-50.25M -43.36M -40.44M -37.47M -69.08M -4.32B -77.51M -490M -185M -2.02B -188M -185M -7.46B
Net Debt	-	-